LGALS3 and prostate cancer: In the hormone-sensitive prostate cancer tissue when compared to the respective benign tissue either localized far distant from the malignant lesion or directly neighboring the primary tumor, the expression of the Galectin-3 was significantly decreased in the prostate cancer tissue (39).